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Background: This non-systematic review article aims to summarise the progress made in understanding the functional
consequences of microRNA (miRNA) dysregulation in prostate cancer development, and the identification of potential
miRNA targets as serum biomarkers for diagnosis or disease stratification.
Results: A number of miRNAs have been shown to influence key cellular processes involved in prostate tumourigenesis,
including apoptosis-avoidance, cell proliferation and migration and the androgen signalling pathway. An overlapping
group of miRNAs have shown differential expression in the serum of patients with prostate cancer of varying stages
compared with unaffected individuals. The majority of studies thus far however, involve small numbers of patients and
have shown variable and occasionally conflicting results
Conclusion: MiRNAs show promise as potential circulating biomarkers in prostate cancer, but larger prospective studies
are required to validate particular targets and better define their clinical utility.
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Despite incremental advances, there remain a number of
challenges yet to be overcome in the management of pros-
tate cancer. The increasing use of PSA-based screening
has facilitated the early detection of prostate cancer at a
curable stage of the disease, however the problem of de-
termining which of these patients truly require treatment
and which can be safely observed remains. The use of no-
mograms based on clinical parameters is helpful, but the
search for additional biomarkers to “fine-tune” risk strati-
fication continues.
MicroRNAs (miRNAs) are short (18-22 nucleotide)
non-coding RNA sequences. They were first identified in
nematodes in 1993 by Lee et al. [1], and, to date, over
1000 separate miRNA sequences have been identified in
the human [2]. It is becoming clear that miRNAs repre-
sent a vast, previously unrecognised layer of molecular
signalling in eukaryotes, and that miRNAs play an im-
portant role in the regulation of protein expression [3].* Correspondence: mrbljackson@gmail.com
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unless otherwise stated.MiRNAs present an appealing target for biomarker
discovery. Each miRNA possesses the ability to interact
with a number of cellular pathways, and consequently
changes in the expression of a small number of miRNAs
may reflect dysregulation of a broad range of cellular
processes, in keeping with the complexity of neoplasia.
Furthermore, miRNAs are relatively resistant to RNase
degradation due to their short sequence length which
improves their longevity in both serum and tissue sam-
ples [4]. A number of techniques for miRNA profiling
have been developed [5], and the principle that increased
tissue expression of miRNAs may lead to elevated serum
levels has been demonstrated experimentally [6].
It may eventually be possible to identify a panel of miR-
NAs that can be measured in serum or tissue and used to
better establish which patients with localised prostate can-
cer will ultimately progress and should therefore be
treated aggressively, or indeed to establish which patients
with more advanced disease are most likely to benefit
from particular therapies, including novel agents acting on
the androgen pathway. Serum miRNA profiling is espe-
cially exciting given that it is accessible in a non-invasive
manner, and it may be possible to establish a diagnosticl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tate biopsies in patients with elevated PSA levels, some of
whom ultimately will not have prostate cancer.
None of these aims have yet been met, but this review
aims to summarise the progress made both with under-
standing the role of miRNA dysregulation in prostate
cancer tumourigenesis, and with establishing which miR-
NAs may be useful serum biomarkers.
Functional role of miRNA dysregulation in prostate cancer
The cellular characteristics required for the initiation
and progression of cancer have been described and in-
volve a broad set of biological pathways including those
that drive cell growth, inhibit cell death, and promote
angiogenesis and metastasis [7]. Given the redundancy
of miRNAs, there is potential for a small set of miRNAs
to be involved in driving and coordinating the expres-
sion of these hallmark characteristics, and the miRNAs
involved are likely to change during tumour progression
as the requirements of cells alter. Thus, understanding
the role of various miRNAs at different stages of pros-
tate cancer progression, along with their expression
changes during those stages, may inform the search for
prognostic biomarkers and even yield potential thera-
peutic targets. Specifically in prostate cancer, the regula-
tion of miRNAs by the androgen receptor signalling
pathway and their influence on this pathway is also of
interest. The interaction of miRNAs with other key sig-
nalling pathways in prostate cancer such as PTEN/AKT
is also discussed.
Whilst much of the complexity of miRNA involvement
in cancer development both in general, and specifically
in prostate cancer, remains to be fully elucidated, the im-
portance of miRNA in several key oncogenic pathways
in prostate cancer has been demonstrated [8].
MiRNAs and avoidance of apoptosis
There appear to be a number of miRNAs that interact
with the apoptotic pathway in prostate cells, and their
dysregulation may promote apoptosis avoidance in pros-
tate cancer via a number of mechanisms, chief among
them being regulation of the p53 tumour suppressor
gene and E2F1-3 transcription factor genes.
The tumour suppressor gene p53 stimulates apoptosis
via upregulation of the Noxa and Puma proapoptotic
proteins [7]. MiR-125b targets p53-dependent apoptosis
by interfering with p53 and its target genes p21 and
Puma. MiR-125b can also stimulate p-53 independent
apoptosis in p-53 deficient cells via the protein product
of the ink4a/ARF locus, p14(ARF) [9]. This suggests a
potential role in prostate cancer progression, and indeed
enforced expression of miR-125b has been shown to in-
duce prostate tumour growth in both intact and castrate
mice [10]. The miR-15-16 cluster influences cell survivalby inhibiting translation of the Bcl2 oncoprotein. Bcl2
exerts anti-apoptotic pressure by inhibiting Noxa and
Puma. Downregulation of these miRNAs has been dem-
onstrated in 80% of prostate cancers, and results in in-
creased Bcl2 activity, favouring cell survival [11]. Loss of
miR-15-16 has additional effects on cell proliferation by
upregulation of cyclin D1, which facilitates G1/S phase
transition. The loss of this miRNA cluster can also acti-
vate the procarcinogenic Wnt pathway [12]. The import-
ance of miR-15-16 in prostate tumour growth has been
further emphasised by the observation that reconstitu-
tion of these miRNAs may lead to regression of prostate
cancer xenografts in mice [12]. MiR-21 has been shown
to target programmed cell death 4 (PDCD4) [13] and
the phosphatase and tensin homologue (PTEN) [14]
both of which stimulate apoptosis via the p53 pathway,
resulting in inhibition of these apoptotic triggers.
The E2F1-3 transcription factors play a key role in the
regulation of the cell cycle and apoptosis [15]. It has been
shown that E2F1-3 bind to promoter sites for the miR-17-
92 cluster and consequently upregulate transcription of
that group of miRNAs. This group of miRNAs, especially
miR-20a, in turn downregulate expression of the E2F1-3
group [16], thereby producing a negative-feedback loop
that maintains E2F1-3 expression levels at a relatively con-
stant level. In prostate cancer cells however, miR-17-92
expression may be upregulated, resulting in E2F1-3 sup-
pression and consequently apoptosis avoidance [16]. MiR-
20a expression levels are progressively higher in benign,
low-grade malignant and high-grade malignant prostate
tissue respectively, perhaps suggesting a role in tumour
progression [17]. Other miRNAs have also been shown to
downregulate E2F1-3 expression including miR-25 [18]
and miR-205 [19].
MiRNA expression has also been demonstrated to
control other pro-apoptotic genes. Fas Associated Factor
1 (FAF1), a component of the death-inducing signalling
complex, is frequently downregulated or lost in a num-
ber of human tumour types [20]. FAF1 has been shown
to be down-regulated by miR-24, resulting in a reduction
in apoptosis in DU-145 hormone-resistant prostate
cancer cells in vitro [21]. The pro-apoptotic protein
TNFSF10 by contrast is upregulated by miR-145 [22].
TNFSF10 (also known as TNF-related apoptosis indu-
cing ligand or TRAIL) is part of the tumour necrosis fac-
tor super-family, and contributes to innate anti-tumour
immunosurveillance [23].
MiRNA and cell invasion and migration
In addition to enhanced cell survival and proliferation,
carcinogenesis also requires cells to develop the ability to
invade the basement membrane and metastasise to distant
sites [7]. To achieve this, the cell must become detached
and motile and avoid anoikis (a form of apoptosis that
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[24]. Granulin has been demonstrated to facilitate cell
motility and avoidance of anoikis in a number of
tumour types as well as having other procarcinogenic
effects such as enhancing epithelial cell division [25]. In
prostate cancer, granulin has been shown to facilitate
migration and anchorage-independent growth in both
androgen-dependent and independent cell lines, al-
though the effect was more marked in androgen-
independent cells [26]. Granulin expression is regulated
by members of the miR-15 - miR-107 group, and miR-
107 in particular has been shown to downregulate gran-
ulin expression in prostate cancer cells in vitro [27].
Downregulation of miR-145 has also been suggested to
lead to enhanced cell proliferation, migration and inva-
sion in prostate cancer. Fuse and colleagues demon-
strated that the capacity of PC3 and DU145 prostate
cancer cells to proliferate, migrate, and invade was im-
paired by transfection with miR-145 [28]. Their study
demonstrated down-regulation of Fascin homolog 1
(FSCN1) by miR-145, which may be the mechanism by
which this occurs.
MiR-143 is also downregulated in prostate cancer, and
has been shown in vitro to inhibit proliferation and mi-
gration of prostate cancer cells by suppressing V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS) ex-
pression, thereby inhibiting the EGFR/RAS/mitogen-
activated protein kinase (MAPK) pathway [29]. This also
resulted in an increase in cell sensitivity to docetaxel.
MiR-133 [30] and miR-146a [31] have also been shown to
target EGFR and to produce similar anti-proliferative,
anti-migratory effects in androgen-insensitive prostate
cancer cell lines in vitro.
Epithelial-mesenchymal transition (EMT) is a develop-
mental regulatory programme whereby an epithelial cell
undergoes a number of alterations that allow it to as-
sume a mesenchymal cell phenotype. These include loss
of normal polarity and adhesion, enhanced migratory
and invasive capability, resistance to apoptosis and in-
creased production of extracellular matrix [32]. EMT
plays a physiological role in embryonal development and
wound healing, but is also implicated as one of the prin-
cipal ways in which carcinoma cells can acquire attri-
butes that allow invasion and metastasis [7].
MiR-205 is downregulated in prostate cancer cells,
and this has been implicated in the stimulation of EMT.
Prostate cancer cells transfected with miR-205 demon-
strated enhanced expression of epithelial adhesion mole-
cules such as E-cadherin, and displayed other features of
a more epithelial phenotype, suggesting that miR-205
downregulation may be partly responsible for stimulat-
ing EMT [19]. The authors identified a number of tar-
gets of miR-205 including N-chimaerin, ErbB3, E2F1,
E2F5, ZEB2, and protein kinase Cε, and identified thelatest of these as being particularly important in regulat-
ing EMT. In subsequent work, the role of miR-205 in
promoting basement membrane deposition, by limiting
the abundance of the ΔNP63α protein, was also clarified.
Interestingly, miR-205 does this by attenuating ΔNP63α
proteasomal degradation rather than via the more typical
miR/mRNA interaction [33].
MiR-143 and miR-145 have been identified as poten-
tial regulators of EMT [34]. Both are downregulated in
bony metastases arising from prostate cancer, and trans-
fection into PC3 cells has been shown to lead to a more
epithelial phenotype in vitro, with increased E-cadherin
and reduced fibronectin expression [34]. The same
group demonstrated that cells overexpressing miR-143
and miR-145 had a reduced propensity to bony invasion
in vivo in a murine intra-tibial injection model [35], and
that in a cohort of 22 patients, reduced expression levels
of miR-143 and miR-145 correlated with higher Gleason
grade, PSA, and bony metastasis [34].
Further work has suggested that miR-29b may also play
a tumour suppressive role by inhibiting EMT [36]. MiR-
29b expression levels were reduced in prostate cancer tis-
sue compared to patient-matched non-tumour tissue, and
investigators found increased E-cadherin expression and
reduced N-Cadherin, Twist, and Snail expression in cells
transfected with miR-29b, suggesting that miR-29b in-
hibits EMT.
MiRNAs and androgen signalling
There appears to be a complex interaction between andro-
gen signalling in prostate cancer, microRNA expression,
and various key pathways in prostate cancer development.
In essence, certain miRNAs have been shown to be regu-
lated by androgen-receptor (AR) mediated signalling
whilst others are involved in modulating the function of
the AR signalling pathway.
AR-regulated miRNAs
MiR-125b has an androgen-responsive element within
the promoter region of its gene [10]. Mi-R125b upregu-
lation has been demonstrated to result in androgen-
independent growth in prostate tumour xenografts in
castrate mice [10] perhaps through its anti-apoptotic ef-
fects (see MiRNAs and avoidance of apoptosis).
MiR-21
In vitro, transfection of LnCaP cells with a miR-21 ex-
pressing retrovirus has been shown not only to stimulate
androgen-dependent cell growth, but also to rescue cells
from androgen-deficient growth arrest [37]. This indi-
cates that miR-21 may also mediate castrate-resistant
prostate cancer (CRPC) development. Li and colleagues
[38] recently established that tissue miR-21 expression
levels may have clinical importance. They evaluated
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tatectomy tissue samples and found increased miR-21
expression was associated with pathological stage, lymph
node status, extracapsular extension and biochemical re-
currence. They went on to demonstrate in vivo tumour
growth repression in a mouse model treated with a miR-
21 inhibitor.
MiR-32 is a further example of an androgen-regulated
miRNA that is upregulated in CRPC. MiR-32 upregula-
tion is associated with downregulation of the protein
BTG2, and reduced BTG2 staining in radical prostatec-
tomy specimens has been shown to predict tumour pro-
gression [39].
MiR-27a
Androgen-stimulated upregulation of miR-27a results in
reduced prohibitin expression [40]. Prohibitin is a
known tumour-suppressor gene and co-repressor of the
androgen receptor, and miR-27a mediated downregula-
tion of its protein product results in increased expres-
sion of androgen receptor target genes and increased
prostate cancer cell growth.
MiR-141
A study by Waltering et al. attempted to profile differen-
tial miRNA expression in androgen treated and un-
treated LnCaP cells in vitro and in prostate cancer
xenografts in intact and castrated mice. MiR-141 dem-
onstrated the greatest androgen-dependent expression in
that study [41]. MiR-141 is overexpressed in various
forms of human epithelial malignancy including prostate
cancer [42]. Separate analysis of prostate epithelial and
stromal cells has demonstrated miR-141 expression to
be epithelium-restricted [6].
MiRNAs influencing androgen signalling
Whilst some miRNAs are expressed in an androgen-
dependent manner, others appear to modulate various
aspects of androgen signalling in prostate cancer. MiR-
221 and miR-222 overexpression have been demon-
strated to attenuate androgen-induced growth in LnCaP
cells in vitro, and to promote androgen-independent
growth [43]. MiR-221 down-regulation has demon-
strated clinical significance in a study that found pro-
gressively reduced expression levels in benign tissue,
primary prostate cancer, and lymph node metastatic tis-
sue respectively [44]. Reduced miR-221 levels were
shown to be linked to increasing Gleason score and re-
currence rate in a large (n = 92) cohort of high-risk pros-
tate cancer patients in the same study.
Other miRNAs that modulate the androgen pathway
include miR-331-3p and Mir- let7c. Down-regulation of
miR-331-3p has been demonstrated to result in an in-
crease in ERBB-2 expression, a tyrosine-kinase receptorthought to play a role in progression from androgen-
dependent to independent growth in some prostate
cancers [45]. Mir let-7c has been shown have tumour
suppressive potential by attenuating androgen receptor
expression, through targeting its c-Myc-driven tran-
scription [46].
MiRNAs and the PTEN/AKT pathway
The PTEN/AKT pathway plays an important role in the
development of prostate cancer, and especially in the
progression to castrate-resistant disease [47]. Enhanced
AKT signalling results in cell proliferation and growth,
enhanced survival, cell-cycle progression and angiogen-
esis [48]. PTEN negatively regulates AKT, and therefore
acts as a tumour suppressor. PTEN loss commonly oc-
curs via somatic genetic changes, but miRNAs can also
downregulate PTEN. Tian and colleagues identified four
miRNAs (miR-19b, miR-23b, miR-26a and miR-92a) that
downregulate PTEN expression and enhance cell prolif-
eration in vitro [49]. Similar findings were noted for
miR-153 by Wu and colleagues [50]. Poliseno and col-
leagues demonstrated that the miR-106b-25 cluster can
also downregulate PTEN in prostate cancer cells. Inter-
estingly, this cluster lies within an intronic region of the
minichromosome maintenance complex component 7
(MCM7) gene, which the authors found to be overex-
pressed in prostate cancer and to co-operate with the
miR106b-25 cluster in tumour development [51]. The
same group identified another fascinating aspect of non-
coding RNA behaviour by discovering the role that the
PTENP1 pseudogene plays in PTEN regulation. Like all
pseudogenes, the mRNA transcript of PTENP1 is not
translated into a functional protein, but by possessing
similar miRNA binding sites to PTEN, it competitively
binds miRNAs that would otherwise bind to and down-
regulate the PTEN mRNA product. Loss of PTENP1
therefore enhances miRNA-mediated downregulation of
PTEN, promoting tumour development [52].
Wang and colleagues identified that loss of the zinc
finger and BTB domain-containing protein 7a (Zbtb7a)
gene accelerates oncogenesis in PTEN loss-driven pros-
tate cancers via a SRY box 9 (SOX9) dependent pathway
for cellular senescence bypass and invasion [53]. Both
PTEN and Zbtb7a gene transcripts are targeted by the
mir106b-25 cluster, providing further evidence of the
importance of miRNA interaction with the PTEN path-
way in prostate cancer development.
MiRNAs and TMPRSS2:ETS gene fusions
TMPRSS2:ETS gene fusions are present in around 50%
of prostate cancers in surgical case series [53]. A
chromosomal rearrangement results in the fusion of the
androgen-sensitive promoter of the transmembrane pro-
tease serine 2 gene (TMPRSS2) gene with one of the
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v-ets erythroblastosis virus E26 oncogene homolog gene
(ERG)) [54]. This results in androgen-dependent overex-
pression of ERG, which has a number of downstream ef-
fects, including the induction of EMT [55]. Kim and
colleagues found that this occurs via ERG-dependent
downregulation of miR-200c expression, and that miR-
200c transfection could inhibit ERG-induced EMT
in vitro [56]. The epidermal growth factor (EGF)/Src
tyrosine kinase pathway also contributes to the induc-
tion of EMT in TMPRSS2:ERG positive prostate cancers,
and Kao and colleagues demonstrated that this inter-
action may be mediated by downregulation of miR-30,
which normally suppresses ERG expression [57].
Gordanpour et al. identified that miR-221 downregula-
tion is also a feature of TMPRSS:ERG fusion-positive
prostate cancer [58]. MiR-221 downregulation has been
shown favour androgen-independent tumour growth
and is associated with a more aggressive prostate cancer
phenotype [44].
MiRNAs and EZH2-dependent DNA methylation changes
The enhancer of zeste homologue 2 (EZH2) gene is over-
expressed in prostate cancer [59] and interacts with DNA
methyl transferases to influence DNA methylation [60].
EZH2 is a target of ERG, and therefore overexpressed in
TMPRSS2:ERG-positive prostate cancers [61]. Borno and
co-workers however, also identified a miRNA-dependent
mechanism for EZH2 overexpression in TMPRSS2:ERG
negative tumours [62]. This occurs via hypermethylation
of the miR-26a locus, resulting in its downregulation. The
group found that loss of miR-26a led to upregulation of
EZH2 in TMPRSS2:ERG negative tumours. Further work
by Cao and colleagues has also identified miR-101 as a
downregulator of EZH2 [63].
Circulating miRNAs in prostate cancer
Understanding of the functional role of miRNA dysregu-
lation in prostate cancer development, and identification
of miRNA up- and down-regulation in prostate cancer
tissue has led to attempts to determine whether circulat-
ing miRNA levels in serum or plasma samples could be
used as biomarkers to aid prostate cancer diagnosis, or
to improve prediction of tumour behaviour. Indeed, the
potential of circulating miRNAs as serum biomarkers
has been explored in a number of tumour types [64].
Mitchell et al. [65] established the presence of mature
miRNAs in a stable form in human plasma, by analysing
the 18-24 nucleotide fraction of plasma RNA from a
healthy donor. In the same study, the authors established
the principle of secretion of tumour-associated miRNAs
into the circulation by analysing the sera of prostate can-
cer xenograft bearing mice. They demonstrated an in-
crease in two miRNAs (miR-629 and -660) that they hadidentified as being upregulated in the prostate cancer
cells prior to implantation, but no increase in other
non-cancer associated miRNAs. They then went on to
compare the sera of 25 patients with metastatic pros-
tate cancer with 25 healthy controls. They chose six
candidate miRNAs (miR-100, miR-125b, miR-141, miR-
143, miR-205, and miR-296) that had shown differential
expression in prostate cancer in previous studies, but
which were not identified in a cloning analysis of the
sera of healthy volunteers. They found elevated levels
of all miRNAs except miR-205, which was not detected
at quantifiable levels in either cancer patients or con-
trols. MiR-141 was the most significantly increased,
with 46-fold overexpression in cancer vs. control. MiR-
141 levels could predict the presence of prostate cancer
with 60% sensitivity at 100% specificity, although it
should be noted that all prostate cancer patients in this
study had metastatic disease.
A further study by Lodes et al. [65] analysed sera
from patients with a number of malignancies using a
micro-array hybridisation technique. They identified 15
miRNAs that were upregulated in the sera of prostate
cancer patients vs. healthy controls (miR-16, -92a, -103,
-107, -197, -34b, -328, -485-3p, -486-5p, -92b, -574-3p,
-636, -640, -766, -885-5p). This study did not confirm
the finding of increased miR-141 expression; however,
the group of prostate cancer patients was small (n = 6),
with several of the patients being pre-treated with
chemotherapy. In addition, no qRT-PCR confirmation
of the micro-array results was performed.
Moltzahn and colleagues evaluated a group of 36 pros-
tate cancer patients stratified into 3 groups of 12 based
on their CAPRA score (a prognostic index for prostate
cancer), and compared them with a group of 12 healthy
controls [66]. They identified significant inaccuracy in
previously published methods by comparing miRNA ex-
pression in cells from wild-type, Dgcr8 knockout, and
Dicer knockout mice, which lack canonical and all miR-
NAs respectively. They demonstrated a group of 10 miR-
NAs that demonstrated differential quantification in a
fluid-chip based high throughput analysis and individual
qRT-PCR analyses. Mir- 223, -26b, -30c and miR-24
were downregulated in the cancer group and miR-874,
-1274a, -1207-5p, -93 and miR-106a were upregulated.
Within those 10, they were able to identify some miR-
NAs whose expression varied significantly between risk
groups, e.g. miR-24 steadily decreased with risk, while
miR-106a steadily increased with risk.
Agalogu et al. [67] analysed serum levels of three miR-
NAs in 51 patients with prostate cancer (subdivided into
localised/locally advanced and metastatic) and 20 healthy
controls. They identified increased levels of miR-21 and
miR-221 in the prostate cancer group as a whole com-
pared to the controls. miR-141 was not significantly
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static group were considered in isolation, all three miR-
NAs were significantly elevated, with mir-141 being the
most elevated of the three.
Gonzales and colleagues [68] further investigated the
role of miR-141 as a biomarker in advanced prostate
cancer by looking at a retrospective cohort of 21 patients
with metastatic prostate cancer. They analysed miR-141
levels using qRT-PCR along with lactate dehydrogenase
(LDH), prostate specific antigen (PSA), and circulating
tumour cell count (CTC) in a number of stored blood
samples at taken at varying intervals during the patient’s
clinical course. Increasing miR-141 levels demonstrated
a significant ability to predict clinical progression via
univariate regression modelling, with an odds ratio of at
least 8. miR-141 levels also correlated with changes in
the other biomarkers under study. The authors sug-
gested that miR-141 may therefore be a suitable bio-
marker for progression in metastatic prostate cancer, but
accepted that larger, prospective studies would be re-
quired to validate that contention.
Zhang and co-workers [69] analysed serum miR-21
levels in 20 patients with localised prostate cancer, 20
with metastatic prostate cancer who remained androgen-
sensitive, 10 with hormone-resistant disease, and 6
controls with BPH only. They demonstrated elevated
miR-21 levels in patients with hormone-resistant pros-
tate cancer and in those with androgen-sensitive meta-
static disease whose PSA was greater than 4 ng/ml.
There was no difference in miR-21 expression between
those with localised prostate cancer and the control
group. Additionally, they found that amongst the hormone-
resistant group, miR-21 levels were higher in those patients
who demonstrated no response to cytotoxic treatment
with docetaxel.
Brase et al. [70] screened sera from a small cohort of
patients with metastatic and locally advanced prostate
cancer using a micro-array based technique to quantify
667 miRNAs and identified five that were upregulated
in the metastatic group (miRNA-375, miRNA-9*,
miRNA-141, miRNA-200b and miRNA-516a-3p). They
went on to analyse the most promising candidate miR-
NAs from their screening study (miR-141, miR-375,
and miR-200b) in a larger cohort of patients (n = 45),
and found that miR-375 and miR-141 levels could dis-
tinguish high-risk (Gleason grade ≥ 8 or metastases)
from Gleason 7 prostate cancers with greater accuracy
than PSA. They went on to perform the same analyses in
a larger cohort (n = 71) of patients including a greater
number of high-risk/metastatic patients. They demon-
strated that both miR-141 and miR-375 levels were pre-
dictive of lymph node positive disease in that group, and
that miR-141 could distinguish Gleason ≥8 disease from
Gleason 7. Additionally, they went on to demonstrateincreased tissue expression of these markers in prostate
cancer tissue samples compared to benign prostate tissue.
Selth et al. used a mouse model of prostate cancer to
identify candidate miRNAs that were overexpressed
compared to healthy control mice. They identified up-
regulation of miR-141, miR-298, miR-346 and miR-375
in both the mouse model and the serum of men with
castrate-resistant prostate cancer compared to controls
[71]. The same group more recently identified three
miRs (miR-141, miR-146b-3p and miR-194) that pre-
dicted biochemical recurrence in men following surgery
for intermediate-risk prostate cancer [72].
Bryant et al. [73] sought to specifically evaluate whether
circulating miRNAs within microvesicles or exosomes
could be used as biomarkers in prostate cancer. They ana-
lysed sera from a cohort of 78 prostate cancer patients
and 28 normal control individuals, who were men who
had PSA levels <10 ng/ml with negative prostate biopsies.
They included a filtration step in their protocol, aimed at
isolating purely the microvesicle component of the serum,
and treated the resulting filtrate with RNase to remove
non-vesicle associated RNA. They analysed the resulting
samples with a micro-array panel of 742 miRNAs, finding
a total of 11 miRNAs to be upregulated in cancer vs. con-
trols (miR-107, -130b, -141, -2110, -301a, -326, -331-3p,
-432, -484, -574-3p, and -625) and one to be down-
regulated (miR-181a-2). When exclusively non-metastatic
prostate cancer patients were compared to controls, a
smaller subset of those miRNAs retained their differential
expression levels. When metastatic patients were com-
pared to non-metastatic patients, a different group of 16
miRNAs were found to be differentially expressed, includ-
ing miR-375, which was also identified as a candidate
marker of advanced disease by Brase et al. [70]. The group
went on to confirm the increased circulating levels of
miR-107 and miR-574-3p in prostate cancer cases vs. con-
trols using individual qRT-PCR assays, and likewise the
differential quantification of miR-221, miR-375, and miR-
141 in metastatic cancers vs. non-metastatic. They also
demonstrated increased circulating miR-375 and miR-141
levels in a separate cohort of metastatic prostate cancer
patients (n = 47) when compared with a group of patients
with no disease recurrence following radical prostatec-
tomy (n = 72). In that subsequent cohort, they analysed
the miRNA content of larger microvesicles and smaller
exosomes separately, and found increased miR-375 and
miR-141 levels in both fractions.
A further recent publication by Huang et al. using
RNA sequencing verified the finding of miR-375 over-
expression in circulating microvesicles in castrate-
resistant prostate cancer, along with miR-1290 also
[74]. The group where able to confirm this finding in a
larger cohort (n = 100) of patients, and found expression
of these miRs to correlate with survival in this group.
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has demonstrated that genomic DNA can also be re-
trieved from extracellular vesicles in prostate cancer pa-
tients, analysis of which could provide a further source
of serum biomarkers [75].
Bryant et al. in their study also looked at levels of five
miRNAs (miR-107, miR-574-3p, miR-375, miR-200b,
miR-141) in post digital rectal examination urine sam-
ples [73]. They demonstrated that miR-107 and miR-
574-3p levels were significantly higher in prostate cancer
cases when compared with controls, indicating that this
may also be a valid sample type for miRNA analysis.
Nguyen and co-workers [76] undertook genome-wide
miRNA profiling of 84 patients with various stages of
prostate cancer, and again identified miR-141 and miR-Table 1 Summary of miRNAs with known functional role in p
serum
MicroRNA Function Up/Downregulated
in Serum
MiR-20a Attenuates the
pro-apoptotic action
of E2F1-3 [16]
Upregulated [73,78]
MiR-21 Inhibits apoptosis by
targeting PDCD4 and
PTEN [13,14]. Can stimulate
androgen-independent
growth [37]
Upregulated [67,69,78]
MiR-107 Granulin production [27] Upregulated [73]
MiR-125b Suppresses p14(ARF)
to modulate both
p-53 dependent and
independent apoptosis [9].
Upregulated [6]
MiR-143 Suppresses KRAS
expression, inhibiting
the MAPK pathway.
Regulates EMT [29]
Upregulated [6]
Mir-141 Expression is controlled
by androgens [41].
Limited to epithelium [6].
Upregulated [65,67,68,73,79]
MiR-145 Inhibits proliferation,
migration, and invasion.
Downregulates FSCN1.
Inhibits EMT [34].
Downregulated [34,78]
MiR-221 Favours androgen-
dependent growth.
Downregulation may
be linked to castrate-
resistant state [43,80].
Upregulated [67,78]
(although downregulation
in tissue also reported [81]
MiR-331-3p Down-regulation increases
ERBB-2 expression.
Associated with androgen-
independent growth [45]
Downregulated [73]
Mir-375 Stimulates proliferation
via downregulation
of Sec23a [82]
Upregulated [70,73,76]375 upregulation in castrate-resistant patients compared
to those with localised disease. MiR-378 was also over-
expressed in that group, whilst miR-409-3p was under-
expressed.
Chen et al. [77] in a more recent study in Chinese pa-
tients undertook profiling of serum samples from prostate
cancer (n = 25) and a control group (n = 17) with benign
hyperplasia only. They identified a further panel of five
miRNAs, which they verified as possessing the ability to
distinguish between prostate cancer and benign patients
in a larger cohort.
Shen and colleagues [78] evaluated four miRNAs in
plasma samples from 82 prostate cancer patients and
found that a combination of miR-20a, miR-21, miR-145
and miR-221 could distinguish localised prostate cancerrostate cancer development and differential regulation in
Relevant
disease stage
Findings from existing studies
Localised and
Metastatic
Distinguishes low/intermediate/high
risk localised disease in combination
with MiR-21, MiR-145, MiR-221 [78]
Localised
and Castrate-resistant
Improves diagnostic accuracy of PSA when
combined with miR-141 [67] Distinguishes
low/intermediate/high risk localised disease
[78] Predictive of response to Docetaxel in
castrate-resistant disease [50].
Localised Upregulated in cancer vs. benign in serum
microvesicles and urine [73]
Not elucidated Distinguishes cancer from control [6]
Not elucidated Distinguishes cancer from control [6]
Advanced/Metastatic
disease
Distinguishes metastatic and localised
disease [70,76] Predicts biochemical
recurrence following radical prostatectomy
Localised and
metastatic
Correlated with higher Gleason grade, PSA,
and bony metastasis [34] Distinguishes low/
intermediate/high risk localised disease [78]
Localised and
metastatic
Distinguishes low/intermediate/high risk
localised disease in combination with
MiR-21, MiR-145, MiR-221 [54]
Not elucidated Distinguishes cancer from control [73]
Localised and
metastatic
Distinguishes metastatic and
localised disease [70,73,76]
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the potential value of combining several miRNA assays
in order to improve diagnostic or prognostic accuracy.
Conclusions
There is evidence from in vitro and in vivo studies that
alteration in miRNA function plays a role in prostatic
carcinogenesis. miRNA dysregulation influences a num-
ber of critical cellular processes involved in this process,
including but not limited to: stimulation of the cell cycle,
avoidance of apoptosis, epithelial-mesenchymal transi-
tion and modulation of AR-mediated signalling. Further
understanding of the functional importance of miRNA
dysregulation may allow the development of novel thera-
peutic strategies involving miRNA augmentation or in-
hibition in the future.
Circulating miRNA profiling in prostate cancer pa-
tients has been carried out by various investigators, but
studies thus far have involved small numbers of patients,
and a variety of methodologies, and have yielded hetero-
geneous results. However, the potential to detect circu-
lating miRNAs in serum and potentially, in urine, clearly
exists.
Furthermore, despite the variability of results, there
are a number of miRNA targets that have both a demon-
strable functional role in prostate cancer pathogenesis
and have demonstrated over- or under-expression in
serum samples in at least one study (summarised in
Table 1). The investigation of these miRNAs, either sin-
gularly or as part of a panel, in larger, prospective patient
cohorts will help to define their potential role as diag-
nostic and prognostic biomarkers in the future.
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